Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.06T
Market cap1.06T
Price-Earnings ratio
38.98
Price-Earnings ratio38.98
Dividend yield
0.58%
Dividend yield0.58%
Average volume
2.86M
Average volume2.86M
High today
$1,149.10
High today$1,149.10
Low today
$1,086.00
Low today$1,086.00
Open price
$1,096.87
Open price$1,096.87
Volume
2.55M
Volume2.55M
52 Week high
$1,149.10
52 Week high$1,149.10
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,125.20, giving the company a market capitalization of 1.06T. It carries a P/E multiple of 38.98 and pays a dividend yield of 57.5%.

On 2026-05-28, Eli Lilly(LLY) stock traded between a low of $1,086.00 and a high of $1,149.10. Shares are currently priced at $1,125.20, which is +3.6% above the low and -2.1% below the high.

The Eli Lilly(LLY)'s current trading volume is 2.55M, compared to an average daily volume of 2.86M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,149.10 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,149.10 and a 52-week low of $623.78.

LLY News

Barron's 18m
Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron's

...

Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron's
The Motley Fool 40m
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

The headline-grabbing battle in the pharmaceutical sector today pits Eli Lilly (LLY +4.08%) against Novo Nordisk (NVO +2.51%). The battlefield is GLP-1 weight l...

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
TipRanks 2h
Eli Lilly Stock Jumps 5% as CVS Health Covers Its Weight-Loss Drugs

The stock of Eli Lilly (LLY) is up 5% on May 28 after CVS Health (CVS) announced that it is restoring coverage of the company’s weight-loss injection Zepbound a...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

TipRanks 5h
Eli Lilly reports PBMs to cover full obesity medicine portfolio

Eli Lilly (LLY) announced all three of the nation’s largest pharmacy benefit managers, or PBMs, will cover Lilly’s full obesity medicine portfolio. This signifi...

CNBC 6h
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. CVS Health on Thursday said it will re...

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
The Motley Fool 21h
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly...

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?
Nasdaq 23h
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

Key Points Eli Lilly dominates one of healthcare's fastest-growing markets. Obesity treatments could generate over $100 billion annually. Buy Lilly shares ba...

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
TipRanks 1d
Eli Lilly Stock Gets a Price Target Boost as Weight-Loss Drug Sales Accelerate

Bank of America (BAC) has raised its price target on Eli Lilly’s (LLY) stock as sales of the pharmaceutical giant’s weight-loss drugs accelerate. Unlock truste...

Nasdaq 1d
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.

Key Points iShares U.S. Pharmaceuticals ETF provides concentrated exposure domestic drug manufacturers while iShares Global Healthcare ETF holds more than 100...

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
Simply Wall St 1d
Eli Lilly’s Vaccine Push Reshapes Growth Story Beyond Obesity And Diabetes

Eli Lilly (NYSE:LLY) is spending nearly $4 billion to acquire three vaccine companies: Curevo, LimmaTech Biologics, and Vaccine Company. The deals expand Lilly...

Eli Lilly’s Vaccine Push Reshapes Growth Story Beyond Obesity And Diabetes

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.